NasdaqGS - Nasdaq Real Time Price USD

Neumora Therapeutics, Inc. (NMRA)

9.58 +0.62 (+6.92%)
At close: 4:00 PM EDT
9.59 +0.01 (+0.10%)
After hours: 5:57 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
273,004.00
252,098.00
135,870.00
237,323.00
95,518.00
Operating Income
-273,004.00
-252,098.00
-135,870.00
-237,323.00
-95,518.00
Net Non Operating Interest Income Expense
19,407.00
16,611.00
4,561.00
--
--
Other Income Expense
-156.00
-170.00
405.00
11.00
-3,754.00
Pretax Income
-253,753.00
-235,657.00
-130,904.00
-237,312.00
-99,272.00
Tax Provision
--
268.00
--
--
--
Net Income Common Stockholders
-254,021.00
-235,925.00
-130,904.00
-237,312.00
-99,272.00
Diluted NI Available to Com Stockholders
-254,021.00
-235,925.00
-130,904.00
-237,312.00
-99,272.00
Basic EPS
-1.59
-3.63
-4.81
-1.56
-0.65
Diluted EPS
-1.59
-3.63
-4.81
-1.56
-0.65
Basic Average Shares
159,357.60
65,021.00
27,207.00
151,949.10
151,949.10
Diluted Average Shares
159,357.60
65,021.00
151,949.10
151,949.10
151,949.10
Total Operating Income as Reported
-273,004.00
-252,098.00
-135,870.00
-237,323.00
-95,518.00
Total Expenses
273,004.00
252,098.00
135,870.00
237,323.00
95,518.00
Net Income from Continuing & Discontinued Operation
-254,021.00
-235,925.00
-130,904.00
-237,312.00
-99,272.00
Normalized Income
-254,021.00
-235,925.00
-130,904.00
-237,312.00
-99,272.00
Interest Income
19,407.00
16,611.00
4,561.00
--
--
Net Interest Income
19,407.00
16,611.00
4,561.00
--
--
EBIT
-273,004.00
-252,098.00
-135,870.00
-237,323.00
-95,518.00
EBITDA
-272,336.00
-251,430.00
-135,276.00
-236,785.00
-95,413.00
Reconciled Depreciation
668.00
668.00
594.00
538.00
105.00
Net Income from Continuing Operation Net Minority Interest
-254,021.00
-235,925.00
-130,904.00
-237,312.00
-99,272.00
Normalized EBITDA
-272,336.00
-251,430.00
-135,276.00
-236,785.00
-95,413.00
Tax Rate for Calcs
--
0.00
--
--
--
12/31/2020 - 9/14/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SLRN Acelyrin, Inc.
4.7300
+0.85%
 
LXEO Lexeo Therapeutics, Inc.
13.97
+3.02%
 
CRGX CARGO Therapeutics, Inc.
19.70
+0.97%
 
MLYS Mineralys Therapeutics, Inc.
13.06
+1.01%
 
DNLI Denali Therapeutics Inc.
19.75
+2.33%
 
BOLD Boundless Bio, Inc.
9.28
-2.52%
 
CNTA Centessa Pharmaceuticals plc
9.04
+2.38%
 
KYTX Kyverna Therapeutics, Inc.
15.50
+5.95%
 
REPL Replimune Group, Inc.
6.71
+1.82%
 
PHVS Pharvaris N.V.
20.80
-1.75%